A Phase 3 interventional study of liraglutide and placebo in Metabolism and Nutrition Disorder, Obesity and Obstructive Sleep Apnoea, sponsored by Novo Nordisk A/S. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-11-01.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 17 in phase 3, and was the 7th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 359 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 46th largest by enrollment of the 166 interventional ones that give a count, is the only one that started in 2012, is one of 62 in phase 3, and was the 9th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 359 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: placebo
3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
Change From Baseline in Apnoea-hypopnoea Index (AHI)
Observed mean change from baseline in AHI (events/hour) after 32 weeks of treatment. AHI (apnoea and hypopnoea events per hour of sleep) is a measure used for the diagnosis and severity classification of obstructive sleep apnoea. AHI severity category: none ≤4.9; mild 5.0-14.9; moderate 15.0-29.9; severe ≥30.0 events/hour.
Time frame: Week 0, Week 32
Change From Baseline in Body Weight (kg)
Observed mean change from baseline in fasting body weight (kg) after 32 weeks of treatment.
Time frame: Week 0, week 32
Change From Baseline in Fasting Plasma Glucose
Observed mean change from baseline in fasting plasma glucose (mmol/L) after 32 weeks of treatment.
Time frame: Week 0, week 32
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
Observed mean change from baseline in glycosylated haemoglobin (HbA1c) (%) after 32 weeks of treatment.
Time frame: Week 0, week 32
The trial was conducted at 40 sites in 2 countries, as follows: United States: 35 sites; Canada: 5 sites.
| Milestone | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Started | 180 | 179 |
| Exposed | 176 | 179 |
| Completed | 134 | 142 |
| Not completed | 46 | 37 |
| Withdrew: Adverse event | 20 | 6 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Protocol violation | 8 | 5 |
| Withdrew: Withdrawn consent | 12 | 20 |
| Withdrew: Target dose not tolerated | 1 | 0 |
| Withdrew: Psychiatric disorder | 1 | 0 |
| Withdrew: Unclassified | 2 | 5 |
Observed mean change from baseline in AHI (events/hour) after 32 weeks of treatment. AHI (apnoea and hypopnoea events per hour of sleep) is a measure used for the diagnosis and severity classification of obstructive sleep apnoea. AHI severity category: none ≤4.9; mild 5.0-14.9; moderate 15.0-29.9; severe ≥30.0 events/hour.
| events/hour | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Apnoea-hypopnoea Index (AHI) | -12.22 ± 23.34 | -6.08 ± 25.90 |
Observed mean change from baseline in fasting body weight (kg) after 32 weeks of treatment.
| kg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight (kg) | -6.73 ± 6.59 | -1.87 ± 5.44 |
Observed mean change from baseline in fasting plasma glucose (mmol/L) after 32 weeks of treatment.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose | -0.15 ± 0.69 | 0.17 ± 0.96 |
Observed mean change from baseline in glycosylated haemoglobin (HbA1c) (%) after 32 weeks of treatment.
| percentage of glycosylated haemoglobin | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) | -0.36 ± 0.30 | -0.17 ± 0.29 |
Collected over Events that either occur before randomisation and increase in severity during the treatment period or have an onset date on or after the first day of randomised treatment and no later than 14 days after the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 3.0 mg | — | 6/176 (3.4%) | 117/176 (66.5%) |
| Placebo | — | 6/179 (3.4%) | 84/179 (46.9%) |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Angina pectorisCardiac disorders | 2/176 | 0/179 |
| Sinus arrestCardiac disorders | 1/176 | 0/179 |
| CholelithiasisHepatobiliary disorders | 1/176 | 0/179 |
| PneumoniaInfections and infestations | 1/176 | 0/179 |
| Procedural painInjury, poisoning and procedural complications | 1/176 | 0/179 |
| Spinal fractureInjury, poisoning and procedural complications | 1/176 | 0/179 |
| DehydrationMetabolism and nutrition disorders | 1/176 | 0/179 |
| AnxietyPsychiatric disorders | 1/176 | 0/179 |
| Depression suicidalPsychiatric disorders | 1/176 | 0/179 |
| Oropharyngeal swellingRespiratory, thoracic and mediastinal disorders | 1/176 | 0/179 |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 47/176 | 12/179 |
| DiarrhoeaGastrointestinal disorders | 29/176 | 14/179 |
| HeadacheNervous system disorders | 25/176 | 20/179 |
| ConstipationGastrointestinal disorders | 21/176 | 6/179 |
| Upper respiratory tract infectionInfections and infestations | 18/176 | 19/179 |
| NasopharyngitisInfections and infestations | 15/176 | 18/179 |
| DyspepsiaGastrointestinal disorders | 15/176 | 2/179 |
| VomitingGastrointestinal disorders | 13/176 | 5/179 |
| Injection site haematomaGeneral disorders | 7/176 | 13/179 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 10/176 | 0/179 |
| Age, Continuous(years) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 48.6 ± 9.9 | 48.4 ± 9.5 | 48.5 ± 9.7 |
| Sex: Female, Male(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Female | 51 | 50 | 101 |
| Male | 129 | 129 | 258 |
| Body weight(kg) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 116.5 ± 23.0 | 118.7 ± 25.4 | 117.6 ± 24.2 |
| Body mass index (BMI)(kg/m^2) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 38.9 ± 6.4 | 39.4 ± 7.4 | 39.1 ± 6.9 |
| Apnoea-hypopnoea index (AHI)(events/hour) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 49.0 ± 27.5 | 49.3 ± 27.5 | 49.2 ± 27.4 |
| Fasting plasma glucose (FPG)(mmol/L) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 5.4 ± 0.6 | 5.4 ± 0.9 | 5.4 ± 0.8 |
| Glycosylated haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 5.7 ± 0.4 | 5.6 ± 0.4 | 5.7 ± 0.4 |
Ran from Jun 2012 to primary completion in Jun 2013, 11 months.
Results were first posted in Feb 2015, 1 year 8 months after primary completion. A results delay was requested in Jun 2014.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 11 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide